ArticleClinical and molecular allergy : CMA2012
IL-3 and TNFα increase Thymic Stromal Lymphopoietin Receptor (TSLPR) expression on eosinophils and enhance TSLP-stimulated degranulation.
Article in Clinical and molecular allergy : CMA, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 61 citations in OpenAlex.
- Eosinophil peroxidase induces inflammation in a mouse model of dermatitis.Journal of leukocyte biology · 2025Article
- Targeted Biologic Therapies in Severe Asthma: Mechanisms, Biomarkers, and Clinical Applications.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Thymic stromal lymphopoietin as a therapeutic target in patients with chronic rhinosinusitis and nasal polyps.Clinical and experimental immunology · 2025Review
- Key role of thymic stromal lymphopoietin as a molecular target for biologic treatment of severe asthma.Frontiers in allergy · 2025Review
- Epithelial-derived cytokines in the pathogenesis of severe asthma.Frontiers in allergy · 2025Review
- Thymic Stromal Lymphopoietin (TSLP): Evidence in Respiratory Epithelial-driven Diseases Including Chronic Rhinosinusitis with Nasal Polyps.Current allergy and asthma reports · 2024Review
- Differences in the direct effects of various type 2 cytokines on functions of blood eosinophils from healthy subjects.Asia Pacific allergy · 2024Article
- Integrative Cross-Talk in Asthma: Unraveling the Complex Interactions Between Eosinophils, Immune, and Structural Cells in the Airway Microenvironment.Diagnostics (Basel, Switzerland) · 2024Review
- Development and dysfunction of structural cells in eosinophilic esophagitis.The Journal of allergy and clinical immunology · 2024Review
- Tezepelumab: patient selection and place in therapy in severe asthma.The Journal of international medical research · 2024Review
- Eosinophil-Epithelial Cell Interactions in Asthma.International archives of allergy and immunology · 2024Review
- The last step to achieve barrier damage control.Frontiers in immunology · 2024Article
- Evidence that oncostatin M synergizes with IL-4 signaling to induce TSLP expression in chronic rhinosinusitis with nasal polyps.The Journal of allergy and clinical immunology · 2023Article
- Severe Asthmatic Responses: The Impact of TSLP.International journal of molecular sciences · 2023Review
- Review
- Review
- Epithelial immune regulation of inflammatory airway diseases: Chronic rhinosinusitis with nasal polyps (CRSwNP).Allergologie select · 2022Review
- Connections between Immune-Derived Mediators and Sensory Nerves for Itch Sensation.International journal of molecular sciences · 2021Review
- Monoclonal Antibodies Targeting Alarmins: A New Perspective for Biological Therapies of Severe Asthma.Biomedicines · 2021Review
- Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThymic stromal lymphopoietin (TSLP) and eosinophils are prominent components of allergic inflammation. Therefore, we sought to determine whether TSLP could activate eosinophils, focusing on measuring the regulation of TSLPR expression on eosinophils and degranulation in response to TSLP, as well as other eosinophil activation responses.
methodsEosinophil mRNA expression of TSLPR and IL-7Rα was examined by real-time quantitative PCR of human eosinophils treated with TNFα and IL-5 family cytokines, and TSLPR surface expression on eosinophils was analyzed by flow cytometry. Eosinophils were stimulated with TSLP (with and without pre-activation with TNFα and IL-3) and evaluated for release of eosinophil derived neurotoxin (EDN), phosphorylation of STAT5, and survival by trypan blue exclusion. A blocking antibody for TSLPR was used to confirm the specificity of TSLP mediated signaling on eosinophil degranulation.
resultsEosinophil expression of cell surface TSLPR and TSLPR mRNA was upregulated by stimulation with TNFα and IL-3. TSLP stimulation resulted in release of EDN, phosphorylation of STAT5 as well as promotion of viability and survival. TSLP-stimulated eosinophil degranulation was inhibited by a functional blocking antibody to TSLPR. Pre-activation of eosinophils with TNFα and IL-3 promoted eosinophil degranulation at lower concentrations of TSLP stimulation.
conclusionsThis study demonstrates that eosinophils are activated by TSLP and that eosinophil degranulation in response to TSLP may be enhanced on exposure to cytokines present in allergic inflammation, indicating that the eosinophil has the capacity to participate in TSLP-driven allergic responses.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.